Abstract: The invention relates to a method of preparing a radiodiagnostic comprising a gaseous radionuclide formed by radioactive decay of a parent nuclide, by eluting with a suitable eluent the radioactive daughter nuclide from the parent nuclide provided ionically on a carrier, by using as a carrier for the parent nuclide ions a membrane, in particular an ion exchange membrane, past which the eluent is made to flow.The invention further relates to a radionuclide generator suitable for using said method.

Abstract: Novel chelating compounds and the corresponding radionuclide metal chelates are useful for radiolabeling proteins such as antibodies with radionuclide metals such as .sup.99m Tc, .sup.186 Re, and .sup.188 Re. The chelating compounds are of the following formulas: ##STR1## wherein each R is a protecting group;Q is hydrogen or a protecting group;each T is independently chosen from hydrogen, lower alkyl groups of from 1 to about 6 carbon atoms, electron withdrawing groups, and lower alkyl groups of from 1 to about 6 carbon atoms substituted with electron withdrawing group(s);X represents O, S, or NH;each R' is independently selected from:--(CH.sub.2).sub.n --COOH with n=0 to about 4,--(CH.sub.2).sub.n --Z, wherein Z represents a conjugation group and n is 0 to about 4,hydrogen, anda lower alkyl group of from 1 to about 6 carbon atoms;each R" is independently selected from:--(CH.sub.2).sub.

Abstract: The present invention relates to the use of Actinium or one of its daughters in radioimmunotherapy. Also provided are immunoconjugates comprising an isotope, a chelating agent and a slowly localizing antibody. The invention also includes pharmaceutical compositions comprising said immunoconjugates, as well as such compositions comprising one or more scavenging agents. The compositions according to the invention are particularly useful for the treatment of micrometastases in adjuvant therapy, as well as for treatment of localized tumors.

Abstract: Compounds of general Formula I labeled with 7.sup.5 Br, .sup.76 Br, .sup.77 Br, .sup.80m Br or .sup.80 Br isotopes ##STR1## wherein R.sup.6 is a C.sub.1-6 hydrocarbon residue and C.sub.2 C.sub.3, C.sub.9 C.sub.10 is a single or a double bond, as well as their acid addition salts, as diagnostic media to image dopamine.

Abstract: The invention relates to a process for the production of a neutron absorbing pellet for use in a nuclear reactor control device, comprising the following stages:a) compactable products are prepared incorporating as % by weight electrolytic crystals or chips of Hf and optionally boron carbide powder with a total weight (HF+B.sub.4 C) of 40 to 100%, the Hf:(Hf+B.sub.4 C) ratio being 0.20 to 1 and optionally other metallic elements melting at above 400.degree. C.;b) these products are mixed and compressed in a mould in one or more filling and compression operations until a pellet is obtained with an apparent density higher than 80% of its average density in the solid state;c) a sintering treatment is optionally carried out on said pellet;d) the pellet is or has been extracted from the mould;e) the pellet is optionally ground.

Abstract: A method of producing a high density, low hygroscopic green salt from hydrated green salt includes heating a charge of hydrated green salt in a nonreactive atmosphere to a first temperature above the boiling point of water to drive off free water; heating the charge in a nonreactive atmosphere to a second temperature higher than the first temperature to drive off the water of crystallization present in the green salt; heating the charge in a nonreactive atmosphere to a third temperature higher than the second temperature to induce anhygroscopicity of the charge; and cooling the charge to approximately 400.degree. F. or less in a protective atmosphere to prevent atmospheric oxidation and hydrolysis.

Abstract: The invention relates to a method of detecting early rejection of an allograft in a mammal by administering to the mammal a diagnostically effective amount of detectably labeled immunoglobulin or fragment thereof, wherein the immunoglobulin substantially accumulates at the site of allograft rejection. The method of the invention may also be used to monitor allograft rejection during immunosuppressive therapy in a mammal which has received an allograft or to localize areas involved in autoimmune disease or inflammation.